Cancer Genetics Inc Stock in Q2 2018 Driven by Institutional Investors

November 10, 2018 - By Alfred Lee

Cancer Genetics, Inc. (NASDAQ:CGIX) Logo

Sentiment for Cancer Genetics Inc (NASDAQ:CGIX)

Cancer Genetics Inc (NASDAQ:CGIX) institutional sentiment decreased to 1 in 2018 Q2. Its down -0.11, from 1.11 in 2018Q1. The ratio worsened, as 8 funds opened new or increased equity positions, while 8 decreased and sold their stakes in Cancer Genetics Inc. The funds in our partner’s database now own: 2.36 million shares, down from 2.70 million shares in 2018Q1. Also, the number of funds holding Cancer Genetics Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 3 Increased: 4 New Position: 4.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $16.93 million. The Company’s tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The companyÂ’s clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

The stock decreased 6.87% or $0.04 during the last trading session, reaching $0.61. About 98,110 shares traded. Cancer Genetics, Inc. (NASDAQ:CGIX) has declined 69.23% since November 10, 2017 and is downtrending. It has underperformed by 84.85% the S&P500.

Perkins Capital Management Inc holds 0.64% of its portfolio in Cancer Genetics, Inc. for 1.00 million shares. Diker Management Llc owns 64,365 shares or 0.02% of their US portfolio. Moreover, Granahan Investment Management Inc Ma has 0.01% invested in the company for 276,417 shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. Barclays Plc, a United Kingdom-based fund reported 454 shares.

More recent Cancer Genetics, Inc. (NASDAQ:CGIX) news were published by: Globenewswire.com which released: “Cancer Genetics Issues Letter to Shareholders” on October 16, 2018. Also Seekingalpha.com published the news titled: “Week In Review: Innovent’s Hong Kong IPO – Raising $422 Million At $2 Billion Valuation” on October 21, 2018. Nasdaq.com‘s news article titled: “Cancer Genetics Enters Strategic Partnership with Genecast Biotechnology to Commercialize Tissue of Origin® Test in …” with publication date: October 18, 2018 was also an interesting one.

Cancer Genetics, Inc. (NASDAQ:CGIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: